Electrical Diseases of the Heart: Genetics, Mechanisms, Treatment, Prevention

Cover......Page 1
front-matter......Page 2
Part I......Page 26
1.00 The Past and Promise of Basic Cardiac Electrophysiology.pdf......Page 27
1.01 Basic Physiology of Ion Channel Function.pdf......Page 35
1.02 Developmental Aspects of the Electrophysiology of the Heart- Function Follows Form.pdf......Page 48
1.03 Anatomic and Histopathological Characteristics of the Conductive Tissues of the Heart.pdf......Page 61
1.04 Neural Regulation of the Heart in Health and Disease.pdf......Page 76
1.05 Mechanisms of Cardiac Arrhythmia.pdf......Page 89
1.06 Mechanisms of Action of Antiarrhythmic Drugs.pdf......Page 157
1.07 Mechanoelectrical Interactions and Their Role in Electrical Function of the Heart.pdf......Page 169
1.08 The Role of Cellular Sodium and Calcium Loading in Cardiac Energetics and Arrhythmogenesis- Contribution of the Late Sodium Current.pdf......Page 185
1.09 Sodium Ion Channelopathies.pdf......Page 194
1.10 L-type Calcium Channel Disease.pdf......Page 211
1.11 K+ Channelopathies ( I Ks and I Kr).pdf......Page 218
1.12 Channelopathies of Cardiac Inwardly Rectifying Potassium Channels.pdf......Page 231
1.13 Calcium Release Channels (Ryanodine Receptors) and Arrhythmogenesis.pdf......Page 242
1.14 Caveolae and Arrhythmogenesis.pdf......Page 256
1.15 Senescence and Arrhythmogenesis.pdf......Page 271
1.16 Comparisons of Substrates Responsible for Atrial Versus Ventricular Fibrillation.pdf......Page 285
1.17 Single Nucleotide Polymorphisms in Health and Cardiac Disease.pdf......Page 305
1.18 Electrophysiological remodeling in Dilated Cardiomyopathy and Heart Failure.pdf......Page 314
1.19 Ventricular Electrical Remodeling in Compensated Cardiac Hypertrophy.pdf......Page 329
1.20 Physiological and Other Biological Pacemakers.pdf......Page 340
Part II......Page 352
2.21 Diagnostic Electrocardiography.pdf......Page 353
2.22 Ambulatory Monitoring (Holter, Event Recorders, External, and Implantable Loop Recorders and Wireless Technology).pdf......Page 366
2.23 Signal Averaged Electrocardiogram.pdf......Page 375
2.24 Heart Rate Variability- Measurements and Risk Stratification.pdf......Page 387
2.25 Surface Mapping and Magnetoelectrocardiography.pdf......Page 401
2.26 Microvolt T Wave Alternans- Mechanisms and Implications for Prediction of Sudden Cardiac Death.pdf......Page 416
2.27 Invasive Electrophysiologic Testing- Role in Sudden Death Prediction.pdf......Page 431
2.28 Provocative Testing in Inherited Arrhythmias.pdf......Page 446
2.29 Novel Predictors of Sudden Cardiac Death.pdf......Page 456
2.30 Genetic Testing.pdf......Page 466
Part III......Page 481
Celebrating the Challenge of Cardiac Arrhythmias.pdf......Page 482
3.31 Congenital Long QT Syndrome.pdf......Page 483
3.32 Brugada Syndrome- Clinical and Genetic Aspects.pdf......Page 504
3.33 Brugada Syndrome- Cellular Mechanisms and Approaches to Therapy.pdf......Page 521
3.34 Catecholaminergic Polymorphic Ventricular Tachycardia.pdf......Page 557
3.35 Andersen-Tawil and Timothy Syndromes.pdf......Page 566
3.36 Short QT Syndrome.pdf......Page 575
3.37 Progressive Cardiac Conduction Disease.pdf......Page 585
3.38 Familial Atrial Fibrillation and Standstill.pdf......Page 598
3.39 Idiopathic Ventricular Fibrillation.pdf......Page 609
Part IV......Page 625
Cardiac Remodeling.pdf......Page 626
4.40 Arrhythmogenic Malignancies in Hypertrophic Cardiomyopathy.pdf......Page 629
4.41 Sudden Death in Dilated Cardiomyopathy and Skeletal Myopathies.pdf......Page 646
4.42 Ventricular Arrhythmias in Right Ventricular Dysplasia-Cardiomyopathy.pdf......Page 662
4.43 The Wolff-Parkinson-White Syndrome and the Risk of Sudden Death.pdf......Page 673
Part V......Page 689
Drug-Induced Enhanced Risk for Sudden Cardiac Death in Clinical Practice, Clinical Research, and Drug Development.pdf......Page 690
5.44 Pharmacogenomics in Drug Development and Clinical Research.pdf......Page 694
5.45 Mechanisms of Drug-Induced Cardiac Toxicity.pdf......Page 708
5.46 Acquired (Drug-Induced) Long QT Syndrome.pdf......Page 722
5.47 Acquired Form of Brugada Syndrome.pdf......Page 736
Part VI......Page 746
Treatment Modalities.pdf......Page 747
6.48 Clinical Role of Antiarrhythmic Drugs in the Prevention of Sudden Death.pdf......Page 749
6.49 Nonantiarrhythmic Drugs in Sudden Death Prevention.pdf......Page 776
6.50 The Implantable Cardioverter Defibrillator- Technical and Clinical Considerations.pdf......Page 788
6.51 Beyond Sudden Death Prevention- Minimizing Implantable Cardioverter Defibrillator Shocks and Morbidity and Optimizing Efficacy.pdf......Page 797
6.52 Pacing and Cardiac Resynchronization.pdf......Page 817
6.53 Device Therapy for Remote Patient Management.pdf......Page 825
6.54 Catheter Ablation of Ventricular Tachycardia and Fibrillation.pdf......Page 842
6.55 Surgical Treatment of Atrial Fibrillation.pdf......Page 855
Part VII......Page 865
Screening for Risk of Sudden Cardiac Death.pdf......Page 866
7.56 Clinical Trials in Sudden Cardiac Death Prevention- Principles and Endpoints.pdf......Page 868
7.57 Risk Stratification forSsudden Death in Patients with Coronary Artery Disease.pdf......Page 873
7.58 Heart Failure and Sudden Death.pdf......Page 888
7.59 Neurological Conditions and Sudden Death.pdf......Page 903
7.60 Obstructive Sleep Apnea and Sudden Death.pdf......Page 913
7.61 Sudden Cardiac Death in Athletes.pdf......Page 926
7.62 Sudden Cardiac Death in Infancy- Focus on Prolonged Repolarization.pdf......Page 939
7.63 Sudden Cardiac Death in Kidney Diseases.pdf......Page 949
back-matter......Page 957